Skip to content

Chymofast Test

by Allergenetics

510(k) K833418

Active United States

510(k)

Valid until

No expiry

510(k) clearance is not time-limited

FDA recalls

None found

in data synced 6 Oct 2026

Documents

Trust

Unverified

Registry data, not yet checked by deviCERTS. Source FDA 510(k), synced 6 Oct 2026. What this means

Regulatory status

as of registry sync 6 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA 510(k)SESE Substantially Equivalent · Traditional NumberK833418 Date12 Mar 1984ClearedStatusActive

Recalls

0 recalls · FDA

No FDA recalls found in the data synced 6 Oct 2026.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Specification

510(k)

510(k) Number
FDA Product Code
DHB
Device Class
Class II
Regulation
21 CFR Part 866.5750
Advisory Committee
Immunology
FDA Decision
SESE Substantially Equivalent

Overview

AI-generated summary, 20 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

The Chymofast Test is a Radioallergosorbent (RAST) Immunological System designed for the quantitative measurement of allergen-specific IgE antibodies in human serum. It is classified as a Class II device under FDA regulation 866.5750, intended for use in immunology diagnostics to aid in the assessment of allergic conditions.

This test is supplied as a diagnostic kit and is regulated under FDA 510(k) clearance (K833418), with a decision of Substantially Equivalent (SESE) granted in 1984. It is intended for single-use in clinical laboratory settings, adhering to immunology specialty standards. The device requires proper storage and handling as specified in its accompanying documentation, ensuring accurate and reliable diagnostic results.

Other devices from Allergenetics

See all devices from Allergenetics →

Questions

AI-generated answers, 20 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

  • What clinical specialty is the Chymofast Test primarily used in, and how does that influence its application in a lab setting?

    The Chymofast Test is designed for use in immunology diagnostics, specifically to measure allergen-specific IgE antibodies in human serum. This focus makes it ideal for clinical laboratories assessing allergic conditions, such as asthma, hay fever, or food allergies. Its classification under FDA regulation 866.5750 (Radioallergosorbent Test Systems) and advisory committee designation for Immunology ensures it aligns with specialty standards for accurate allergen testing.

  • Is the Chymofast Test intended for single-use, and if so, what does this mean for lab workflows?

    Yes, the Chymofast Test is intended for single-use only, as explicitly stated in its regulatory documentation. This means each kit is designed for one diagnostic procedure, reducing cross-contamination risks and ensuring consistent, reliable results. Labs must account for this in their workflows by ordering replacement kits for each test and adhering to proper disposal protocols for used components.

  • What storage and handling requirements should a lab follow to maintain the accuracy of the Chymofast Test?

    While the exact storage conditions aren’t detailed in the provided data, the Chymofast Test’s single-use nature and sensitivity as an immunological diagnostic imply it requires careful handling per the manufacturer’s instructions. Typically, such tests need protection from extreme temperatures, light exposure, and contamination. Labs should store the kit in its original packaging, away from direct sunlight or moisture, and follow the accompanying documentation to preserve sterility and performance until use.

  • How does the Chymofast Test’s regulatory pathway (e.g., FDA clearance) affect its adoption or integration into a lab’s diagnostic menu?

    The Chymofast Test holds an FDA 510(k) clearance (K833418) with a Substantially Equivalent (SESE) designation, granted in 1984, under the Radioallergosorbent Test System classification. This clearance confirms it meets FDA standards for safety and effectiveness as a Class II device, which can reassure labs of its regulatory compliance. However, since it’s an older clearance, labs should verify compatibility with current laboratory practices and confirm any updates from Allergenetics regarding usage or alternatives, as medical device standards may evolve.